Jul 25, 2008
Bristol comes out swinging at Lilly clot drug
By Ransdell Pierson
NEW YORK (Reuters) - Bristol-Myers Squibb Co, which sells leading blood clot preventer Plavix, on Thursday dismissed Eli Lilly and Co's rival Effient drug as a "niche" product that has harmed or failed to help three groups of patients in a big study.
Effient, which is awaiting approval by U.S. regulators, has been widely touted as a medicine that could supplant the $5 billion-a-year Plavix as the standard treatment to prevent heart attacks among heart patients, including those receiving stents.
Read full story from Reuters
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| Merck to fund Vioxx settlement in August | 1 hr | DJ -SMD | 1319 |
| MPI Research cutting jobs in Mattawan | 3 hr | Harold | 5 |
| Claims administrator: Interim payments in $4.85... | 3 hr | heraldo | 983 |
| Buffalo - The Next Cleveland? | 4 hr | Wow | 14 |
| Cymbalta leads the way for Lilly (from Feb '07) | 4 hr | edd | 232 |
| Vioxx claimants rush to join $4.85B settlement ... (from Jan '08) | 5 hr | IronLady | 647 |
| Teva Announces Launch of Generic Zoloft (from Nov '06) | 7 hr | KGH Monroe NC | 1113 |
Scorpio
Most Popular